Addex Therapeutics Ltd
Addex Therapeutics Ltd (ADXN) is a clinical‑stage biotechnology company developing allosteric modulators aimed at central nervous system disorders. With a small market capitalisation (around $15.05M), the company is at an early and speculative phase: its value depends heavily on clinical trial results, regulatory milestones and potential partnerships or licensing deals. Investors should be aware of the typical biotech risks — trial failures, long development timelines, cash burn and stock volatility — and that shares may be thinly traded. Addex may attract those interested in novel mechanism‑of‑action therapies for neurological or psychiatric conditions, but any investment should be made after reviewing up‑to‑date regulatory filings, recent trial data and the company’s cash runway. This summary is general, educational information only and not personalised investment advice; consider seeking professional financial advice to assess suitability for your circumstances.
Stock Performance Snapshot
Financial Health
Addex Therapeutics is generating low revenue and has limited financial strength to support growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ADXN
Beyond Leqembi: The Alzheimer's Treatment Frontier
New long-term data shows Eisai and Biogen's Alzheimer's drug, Leqembi, effectively slows cognitive decline over four years, confirming its market-leading position. This breakthrough validates the underlying scientific approach, creating investment opportunities in other companies developing similar neurodegenerative therapies and diagnostic tools.
Published: July 30, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Allosteric approach
The company targets modulation of receptor activity rather than direct activation, an approach that may offer selectivity — though clinical benefit remains unproven.
Clinical catalysts ahead
Pipeline readouts and regulatory milestones can move the share price significantly; however, binary trial outcomes also increase downside risk.
Small‑cap dynamics
Low market capitalisation can mean higher volatility and limited liquidity, so position size and risk management are important for investors.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
